ST交投(002200.SZ):聯合體擬中標G78汕昆高速/G80廣昆高速石林至昆明段(改擴建)工程項目
格隆匯4月8日丨ST交投(002200.SZ)公佈,近日,雲南交投生態科技股份有限公司經查詢全國公共資源交易平臺雲南省公共資源交易信息網獲悉,公司作爲聯合體成員之一,與雲南省交通投資建設集團有限公司(牽頭人)、雲南交投集團投資有限公司、雲南交投集團公路建設有限公司、雲南交投集團雲嶺建設有限公司、雲南雲嶺高速公路交通科技有限公司、雲南交投新能源產業發展有限公司、雲南省交通規劃設計研究院股份有限公司、雲南省交通科學研究院有限公司等單位組成聯合體,被確定爲“G78汕昆高速/G80廣昆高速石林至昆明段(改擴建)工程項目投資人招標”的第一中標候選人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.